Meeting
2019 ASCO Annual Meeting
A plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay to inform recurrence risk in colorectal cancer (CRC).
Authors
Aparna Raj Parikh
Massachusetts General Hospital, Boston, MA
Aparna Raj Parikh , Emily E. Van Seventer , Genevieve Marie Boland , Anna Hartwig , Ariel Jaimovich , Victoria M. Raymond , AmirAli Talasaz , Ryan Bruce Corcoran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3602)
DOI
10.1200/JCO.2019.37.15_suppl.3602
Abstract #
3602
Poster Bd #
94
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Circulating tumor DNA as a promising biomarker of relapse risk for stage II-III colorectal cancer.
First Author: Gong Chen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Comprehensive genomic analysis of molecular residual disease based on circulating tumor DNA in patients with postoperative colorectal cancer.
First Author: Qingqi Hong
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Impact of postoperative integrated genomic and epigenomic signatures of circulating tumor DNA (ctDNA) on recurrence in resected colorectal cancer: Initial report of a prospective ctDNA monitoring study COSMOS-CRC-01.
First Author: Yuichiro Tsukada
Poster
2024 ASCO Breakthrough
CORRECT-MRD I: A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD).
First Author: Yuichiro Tsukada